Drug Profile
Filgrastim biosimilar - Phage Pharmaceuticals
Latest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Phage Pharmaceuticals
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 05 Jun 2015 No development reported - Preclinical for Neutropenia in USA (SC)